Sermorelin: Tracking the Full-Length GHRH Analog

Sermorelin is the synthetic version of the active 29-amino-acid sequence of human growth hormone-releasing hormone (GHRH 1-29). It was FDA-approved decades ago for pediatric GH deficiency under the brand Geref, was discontinued from the US market commercially, and remains available primarily through compounding pharmacies. It works by stimulating the pituitary to release its own GH, which is a meaningfully different mechanism from injecting recombinant GH directly.

What it does

Sermorelin binds the GHRH receptor on pituitary somatotrophs and triggers pulsatile GH release. Because the pituitary still controls the pulse, the GH response retains some physiological shape — high peaks during sleep, normal feedback inhibition through somatostatin and IGF-1. The downstream effect is a modest rise in IGF-1, often within the upper-normal range for age rather than supraphysiological.

Typical protocol shape

Sermorelin has a very short half-life — minutes — and is typically administered subcutaneously at night to align with the natural overnight GH pulse. Daily dosing is standard, sometimes 5-on-2-off. The night-time timing matters because eating, particularly carbohydrates, blunts GH release sharply. Many users dose 60-90 minutes after their last meal.

What to track daily

• Injection time and site (rotate)
• Time of last meal before injection
• Sleep onset time and total sleep
• Sleep depth, if you wear a tracker
• Morning fasting glucose
• Any injection-site redness or flushing

What to track weekly

• Average sleep quality score
• Recovery from training
• Body composition trends (waist circumference is more useful than scale weight)
• Skin and hair subjective changes — slow signals
• Any water retention or joint stiffness

Bloodwork worth doing

• IGF-1 at baseline and at 8-12 weeks
• Fasting glucose and HbA1c — GH axis activation can nudge insulin resistance
• A full lipid panel
• TSH and free T4 if you are on prolonged use
• Cortisol if you are tracking the broader endocrine picture

Realistic expectations

Sermorelin produces a real but modest IGF-1 rise. Do not expect HGH-level body composition shifts. The most consistently reported subjective benefits are better sleep depth and slightly faster recovery, which are also the benefits hardest to confirm without blinded testing. Tolerance over months is a real phenomenon — the pituitary adapts, which is part of why cycling is common.

Common mistakes

• Eating carbohydrates within an hour of injection
• Daytime dosing that misses the natural overnight GH pulse
• Not running a baseline IGF-1 before starting
• Expecting recombinant GH outcomes
• Ignoring glucose drift on long courses

A tracking template

A Peptid AI daily log: injection done yes/no, time, hours since last meal, sleep score, fasting glucose. Weekly: sleep trend and recovery rating. Quarterly: attach the IGF-1 result. The sleep and IGF-1 lines together tell you whether the protocol is doing anything beyond a placebo.

Safety notes

Sermorelin in the US is now only available through compounded preparations, and quality varies. It is a prescription compound and should involve a clinician. Contraindicated in active malignancy and used cautiously in anyone with diabetes or insulin resistance. The GH axis is real endocrinology, not a supplement — treat it accordingly.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.